President, Global Research & Development, Sanofi
Dr. Reed holds a B.A. in chemistry from the University of Virginia, Charlottesville (1980) and a M.D. and Ph.D. (Immunology) from the University of Pennsylvania, School of Medicine (1986).
He began his academic career as a member of the faculty at the University of Pennsylvania in 1988, following a post-doctoral fellowship in Molecular Biology at the Wistar Institute and a residency in Pathology & Laboratory Medicine at Hospital of University Pennsylvania. Dr. Reed subsequently held faculty appointments at several universities including University California, University of Florida, and ETH-Zurich.
In 1992, Dr. Reed joined the Sanford-Burnham Medical Research Institute in La Jolla, California, one of the largest independent non-profit biomedical research institutes in the United States. From 2002 to 2013, he served as CEO of the Institute. During his tenure, Dr. Reed ran a highly productive laboratory that generated more than 900 research publications, over 130 patents, and was awarded more than one-hundred research grants and trained over 100 post-doctoral fellows. Dr. Reed is a Fellow of the American Association for the Advancement of Science (AAAS) and a recipient of numerous honors and awards for his accomplishments in biomedical research.
Dr. Reed has served on multiple editorial boards of research journals. He was scientific founder or co-founder of four biotechnology companies. He has served on the Board of Directors for five publicly traded biopharmaceutical and biotechnology companies and on the governing boards for various non-profit biomedical research organizations.
From 2013 to 2018, Dr. Reed was Global Head of Roche Pharmaceutical Research & Early Development for Roche, based at company headquarters in Basel, Switzerland. He was responsible for research through Phase 2b development for all therapeutic areas, overseeing R&D activities across 7 global sites.
Dr. John Reed assumed his present position as Executive Vice President, Global Head of Research & Development for Sanofi in July 2018.